FLAURA2
10 Dec 2020
Trial Summary
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
Acronym:
FLAURA2
ACTRN/NCT /ethics:
NCT04035486
Scientific title:
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
Sponsor / Cooperative group:
AstraZeneca
Trial & Patient Characteristics
| Cancer Type | Lung & mesothelioma |
|---|---|
| Trial Type | Treatment |
| Phase | Phase III |
| Age Range | 18 years and older |
| Sex | Both |
| Tumour Stream | Advanced Solid Tumors |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-07-02 |
| Anticipated End Date | 2026-03-23 |
Participating Hospitals
| Hospital | Lyell McEwin Hospital |
|---|---|
| Clinical Trial Coordinator | Andy Phay |
| andy.phay@sa.gov.au | |
| Phone | 08 8282 0833 |
| Principal Investigator | Dr Dainik Patel |
| Recruitment Status | Recruiting |